Glycemic Control Assessed by Intermittently Scanned Glucose Monitoring in Type 1 Diabetes during the COVID-19 Pandemic in Austria

被引:1
作者
Secco, Katharina [1 ]
Baumann, Petra Martina [1 ]
Poettler, Tina [1 ]
Aberer, Felix [1 ]
Cigler, Monika [1 ]
Elsayed, Hesham [1 ]
Harer, Clemens Martin [1 ]
Weitgasser, Raimund [2 ]
Schuetz-Fuhrmann, Ingrid [3 ,4 ]
Mader, Julia Katharina [1 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Diabetol, Auenbruggerpl 15, A-8036 Graz, Austria
[2] Private Clin Wehrle Diakonissen, Dept Internal Med & Diabetol, A-5026 Salzburg, Austria
[3] Hosp Hietzing, Med Div Metab Dis & Nephrol 3, A-1130 Vienna, Austria
[4] Karl Landsteiner Inst, Inst Metab Dis & Nephrol, A-1130 Vienna, Austria
关键词
COVID-19; glycemic control; isCGM; lockdown; pandemic; type; 1; diabetes; CORONAVIRUS DISEASE 2019; IMPACT;
D O I
10.3390/s24144514
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Objective: The aim of this analysis was to assess glycemic control before and during the coronavirus disease (COVID-19) pandemic. Methods: Data from 64 (main analysis) and 80 (sensitivity analysis) people with type 1 diabetes (T1D) using intermittently scanned continuous glucose monitoring (isCGM) were investigated retrospectively. The baseline characteristics were collected from electronic medical records. The data were examined over three periods of three months each: from 16th of March 2019 until 16th of June 2019 (pre-pandemic), from 1st of December 2019 until 29th of February 2020 (pre-lockdown) and from 16th of March 2020 until 16th of June 2020 (lockdown 2020), representing the very beginning of the COVID-19 pandemic and the first Austrian-wide lockdown. Results: For the main analysis, 64 individuals with T1D (22 female, 42 male), who had a mean glycated hemoglobin (HbA1c) of 58.5 mmol/mol (51.0 to 69.3 mmol/mol) and a mean diabetes duration 13.5 years (5.5 to 22.0 years) were included in the analysis. The time in range (TIR[70-180mg/dL]) was the highest percentage of measures within all three studied phases, but the lockdown 2020 phase delivered the best data in all these cases. Concerning the time below range (TBR[<70mg/dL]) and the time above range (TAR[>180mg/dL]), the lockdown 2020 phase also had the best values. Regarding the sensitivity analysis, 80 individuals with T1D (26 female, 54 male), who had a mean HbA1c of 57.5 mmol/mol (51.0 to 69.3 mmol/mol) and a mean diabetes duration of 12.5 years (5.5 to 20.7 years), were included. The TIR[70-180mg/dL] was also the highest percentage of measures within all three studied phases, with the lockdown 2020 phase also delivering the best data in all these cases. The TBR[<70mg/dL] and the TAR[>180mg/dL] underscored the data in the main analysis. Conclusion: Superior glycemic control, based on all parameters analyzed, was achieved during the first Austrian-wide lockdown compared to prior periods, which might be a result of reduced daily exertion or more time spent focusing on glycemic management.
引用
收藏
页数:16
相关论文
共 36 条
  • [1] Diabetes and the Severity of Pandemic Influenza A (H1N1) Infection
    Allard, Robert
    Leclerc, Pascale
    Tremblay, Claude
    Tannenbaum, Terry-Nan
    [J]. DIABETES CARE, 2010, 33 (07) : 1491 - 1493
  • [2] Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis
    Bao, Cuiping
    Liu, Xuehuan
    Zhang, Han
    Li, Yiming
    Liu, Jun
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2020, 17 (06) : 701 - 709
  • [3] Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
    Battelino, Tadej
    Danne, Thomas
    Bergenstal, Richard M.
    Amiel, Stephanie A.
    Beck, Roy
    Biester, Torben
    Bosi, Emanuele
    Buckingham, Bruce A.
    Cefalu, William T.
    Close, Kelly L.
    Cobelli, Claudio
    Dassau, Eyal
    DeVries, J. Hans
    Donaghue, Kim C.
    Dovc, Klemen
    Doyle, Francis J.
    Garg, Satish
    Grunberger, George
    Heller, Simon
    Heinemann, Lutz
    Hirsch, Irl B.
    Hovorka, Roman
    Jia, Weiping
    Kordonouri, Olga
    Kovatchev, Boris
    Kowalski, Aaron
    Laffel, Lori
    Levine, Brian
    Mayorov, Alexander
    Mathieu, Chantal
    Murphy, Helen R.
    Nimri, Revital
    Norgaard, Kirsten
    Parkin, Christopher G.
    Renard, Eric
    Rodbard, David
    Saboo, Banshi
    Schatz, Desmond
    Stoner, Keaton
    Urakami, Tatsuiko
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. DIABETES CARE, 2019, 42 (08) : 1593 - 1603
  • [4] Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring
    Bergenstal, Richard M.
    Beck, Roy W.
    Close, Kelly L.
    Grunberger, George
    Sacks, David B.
    Kowalski, Aaron
    Brown, Adam S.
    Heinemann, Lutz
    Aleppo, Grazia
    Ryan, Donna B.
    Riddlesworth, Tonya D.
    Cefalu, William T.
    [J]. DIABETES CARE, 2018, 41 (11) : 2275 - 2280
  • [5] Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy
    Bonora, Benedetta Maria
    Boscari, Federico
    Avogaro, Angelo
    Bruttomesso, Daniela
    Fadini, Gian Paolo
    [J]. DIABETES THERAPY, 2020, 11 (06) : 1369 - 1379
  • [6] Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
    Booth, CM
    Matukas, LM
    Tomlinson, GA
    Rachlis, AR
    Rose, DB
    Dwosh, HA
    Walmsley, SL
    Mazzulli, T
    Avendano, M
    Derkach, P
    Ephtimios, IE
    Kitai, I
    Mederski, BD
    Shadowitz, SB
    Gold, WL
    Hawryluck, LA
    Rea, E
    Chenkin, JS
    Cescon, DW
    Poutanen, SM
    Detsky, AS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21): : 2801 - 2809
  • [7] Telehealth and COVID-19 Pandemic: An Overview of the Telehealth Use, Advantages, Challenges, and Opportunities during COVID-19 Pandemic
    Bouabida, Khayreddine
    Lebouche, Bertrand
    Pomey, Marie-Pascale
    [J]. HEALTHCARE, 2022, 10 (11)
  • [8] Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019)
    Clodi, Martin
    Abrahamian, Heidemarie
    Brath, Helmut
    Brix, Johanna
    Drexel, Heinz
    Fasching, Peter
    Foeger, Bernhard
    Francesconi, Claudia
    Froehlich-Reiterer, Elke
    Harreiter, Juergen
    Hofer, Sabine E.
    Hoppichler, Friedrich
    Huber, Joakim
    Kaser, Susanne
    Kautzky-Willer, Alexandra
    Lechleitner, Monika
    Ludvik, Bernhard
    Luger, Anton
    Mader, Julia K.
    Paulweber, Bernhard
    Pieber, Thomas
    Prager, Rudolf
    Rami-Merhar, Birgit
    Resl, Michael
    Riedl, Michaela
    Roden, Michael
    Saely, Christoph H.
    Schelkshorn, Christian
    Schernthaner, Guntram
    Sourij, Harald
    Stechemesser, Lars
    Stingl, Harald
    Toplak, Hermann
    Wascher, Thomas C.
    Weitgasser, Raimund
    Winhofer-Stoeckl, Yvonne
    Zlamal-Fortunat, Sandra
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 (Suppl 1) : 27 - 38
  • [9] Digital technology and COVID-19 pandemic: Feasibility and acceptance of an innovative telemedicine platform
    Foglia, Emanuela
    Garagiola, Elisabetta
    Bellavia, Daniele
    Rossetto, Federica
    Baglio, Francesca
    [J]. TECHNOVATION, 2024, 130
  • [10] The First Italian Telemedicine Program for Non-Critical COVID-19 Patients: Experience from Lodi (Italy)
    Forlani, Sara
    Mastrosimone, Erminia
    Paglia, Stefano
    Protti, Simonetta
    Ferraris, Maria Paola
    Casale, Maria Chiara
    Di Capua, Mirko
    Grossi, Maria Giuseppina
    Esposti, Marco
    Randazzo, Davide
    Giustivi, Davide
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)